TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03529838

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Combined exercise
Description: The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
Study: NCT02374281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose sucking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water sucking

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No sucking
Study: NCT03213132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi (Sleep Health Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHUTi (Sleep Health Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patient Education
Description: Educational website containing information on insomnia
Study: NCT03652766

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily Weight Tracking
Description: Daily weight tracking + weekly email or text message feedback
Study: NCT04234009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle.
Study: NCT00631124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-4891 (Estradiol / Drospirenone)
Description: Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-4891 (Estradiol / Drospirenone)
Description: Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
Study: NCT03379532

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-NMES
Description: Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
Study: NCT01020227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Therapies Intervention
Description: Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
Study: NCT03487068

Intervention type: DEVICE
Group type: OTHER
Intervention: The FibroScan device
Description: The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
Study: NCT01804075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
Study: NCT02667236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 Solution
Description: Active Drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Placebo
Study: NCT02249091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
Study: NCT01804075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
Study: NCT01839851

Intervention type: DRUG
Intervention: Treatment with any inhaled corticosteroid
Description: Use of any inhaled corticosteroid (daily frequency and dose will be registered)

Intervention type: DRUG
Intervention: Treatment with any inhaled corticosteroid
Description: Use of any inhaled corticosteroid (daily frequency and dose will be registered)

Intervention type: DRUG
Intervention: Treatment with any intranasal glucocorticoid
Description: Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)

Intervention type: DRUG
Intervention: Treatment with any intranasal glucocorticoid
Description: Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
Study: NCT02249091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
Study: NCT01942330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-Assisted Natural Orifice Surgery
Description: Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
Study: NCT03602183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
Study: NCT02249091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Continuous infusion day 1 to 7, 100 mg/m\^2, iv,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
Study: NCT03483779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills
Description: Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
Study: NCT03602183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
Study: NCT03483779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills
Description: Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
Study: NCT05792982

Intervention type: BEHAVIORAL
Intervention: 12 hour fasting for 29 days
Description: This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
Study: NCT03602183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Description: intubation will be performed using Miller laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Description: intubation will be performed using Miller laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Description: intubation will be performed using Miller laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Description: intubation will be performed using Miller laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC EMS
Description: intubation will be performed using McGrath MAC EMS video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC EMS
Description: intubation will be performed using McGrath MAC EMS video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC EMS
Description: intubation will be performed using McGrath MAC EMS video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC EMS
Description: intubation will be performed using McGrath MAC EMS video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: intubation will be performed using GlideScope video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: intubation will be performed using GlideScope video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: intubation will be performed using GlideScope video - laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: intubation will be performed using GlideScope video - laryngoscope
Study: NCT01941121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage to PrEP or Care
Description: Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
Study: NCT02452489

Intervention type: DEVICE
Group type: OTHER
Intervention: acupuncture
Description: Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
Study: NCT04146038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02259127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Study: NCT02452489

Intervention type: DEVICE
Group type: OTHER
Intervention: acupuncture
Description: Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: acupuncture
Description: Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
Study: NCT03313791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50%whey-50% casein (Standard)
Description: see arm description
Study: NCT03394651

Intervention type: DRUG
Intervention: Oral medications to treat lower urinary tract symptoms
Description: Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
Study: NCT02419586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bubble gum
Description: Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
Study: NCT02793804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oraquick (made in Thailand)
Study: NCT01723202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: 150 mg orally twice daily given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: 150 mg orally twice daily given orally

Intervention type: DRUG
Group type: OTHER
Intervention: dabrafenib
Description: 150 mg orally twice daily given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: 150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally

Intervention type: DRUG
Group type: OTHER
Intervention: trametinib
Description: 150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: 1. Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~2. BRAF mutation studies in circulating plasma DNA (all study patients)~3. Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~4. Assess predictors of response (Archival tumor block/unstained slides in all study patients)~5. Pharmacokinetic studies (First 10 pts enrolled on each arm)~6. Pharmacogenomics studies (All study patients)
Study: NCT03394651

Intervention type: PROCEDURE
Intervention: Minimal invasive transurethral prostate procedures
Description: Patients in this group will receive surgical treatment.
Study: NCT03313791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50%whey-50% casein (Alternative)
Description: see arm description
Study: NCT01326091

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperlordotic Positioning
Description: Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
Study: NCT01252160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: Cutaneous patch
Study: NCT03313791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Isolate- WPH
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Isolate - Na-caseinate
Description: see arm description
Study: NCT01723202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: 1. Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~2. BRAF mutation studies in circulating plasma DNA (all study patients)~3. Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~4. Assess predictors of response (Archival tumor block/unstained slides in all study patients)~5. Pharmacokinetic studies (First 10 pts enrolled on each arm)~6. Pharmacogenomics studies (All study patients)

Intervention type: OTHER
Group type: OTHER
Intervention: Correlative Studies
Description: 1. Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~2. BRAF mutation studies in circulating plasma DNA (all study patients)~3. Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~4. Assess predictors of response (Archival tumor block/unstained slides in all study patients)~5. Pharmacokinetic studies (First 10 pts enrolled on each arm)~6. Pharmacogenomics studies (All study patients)
Study: NCT03313791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Isolate
Description: see arm description
Study: NCT02579421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: generic progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: generic progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01318135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and metformin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
Study: NCT03313791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT milk
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recombined milk
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recombined 50%whey milk
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-caseinate
Description: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein isolate
Description: see arm description
Study: NCT02878746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic mirror therapy
Description: 2-dimensional

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mirror therapy
Description: 2- and 3-dimensional
Study: NCT02201134

Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane
Study: NCT02190708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ912
Description: from day2 up to day6 twice daily oral dose of PQ912
Study: NCT03409575

Intervention type: OTHER
Group type: OTHER
Intervention: 5 minutes stimulation
Description: Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.

Intervention type: OTHER
Group type: OTHER
Intervention: 10 minutes stimulation
Description: Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
Study: NCT03809195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis
Description: See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
Study: NCT03669744

Intervention type: OTHER
Intervention: telephone survey
Description: a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
Study: NCT04432324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Immune Globulin
Description: IVIG Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: SMT
Study: NCT04407208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: The minimum titer of specific antibody is 1/80
Study: NCT02935153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD22-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study: NCT04500093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsulotomy with Repair
Description: Capsulotomy with Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsuloectomy
Description: Capsuloectomy
Study: NCT03223792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine cow's milk-based infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: Partially-hydrolyzed cow's milk protein infant formula